US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
WO2002064083A2
(en)
*
|
2000-11-30 |
2002-08-22 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
DE10137163A1
(de)
*
|
2001-07-30 |
2003-02-13 |
Bayer Ag |
Substituierte Isoindole und ihre Verwendung
|
JP4494013B2
(ja)
*
|
2001-08-06 |
2010-06-30 |
ザ チルドレンズ メディカル センター コーポレイション |
窒素置換サリドマイド誘導体の合成及び抗腫瘍活性
|
AU2003211941A1
(en)
|
2002-02-14 |
2003-09-04 |
Ajinomoto Co., Inc. |
Method of analyzing aminofunctional compound and analytical reagent
|
US20050148034A1
(en)
*
|
2002-04-12 |
2005-07-07 |
Hariri Robert J. |
Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
AU2006202316B2
(en)
*
|
2002-05-17 |
2008-04-10 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
CN102429908A
(zh)
|
2002-05-17 |
2012-05-02 |
细胞基因公司 |
用于治疗和控制多发性骨髓瘤的方法及组合物
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
CN1326522C
(zh)
*
|
2002-10-24 |
2007-07-18 |
细胞基因公司 |
用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
KR101042448B1
(ko)
*
|
2002-11-26 |
2011-06-16 |
안트로제네시스 코포레이션 |
세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
|
AU2004206860B2
(en)
*
|
2003-01-14 |
2010-03-18 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
JP2006517975A
(ja)
*
|
2003-02-13 |
2006-08-03 |
アンスロジェネシス コーポレーション |
疾患、障害または症状を患っている個体を治療するための臍帯血の使用
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
UA83504C2
(en)
*
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
CA2538864C
(en)
*
|
2003-09-17 |
2013-05-07 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Thalidomide analogs as tnf-alpha modulators
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
EP1684758A4
(en)
*
|
2003-11-06 |
2009-02-18 |
Celgene Corp |
METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
US20050143420A1
(en)
*
|
2003-12-02 |
2005-06-30 |
Moutouh-De Parseval Laure |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
AU2005226649B2
(en)
*
|
2004-03-22 |
2010-04-29 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
KR101164696B1
(ko)
*
|
2004-04-14 |
2012-07-11 |
셀진 코포레이션 |
골수이형성 증후군의 치료 및 관리를 위한 면역조절화합물의 사용 방법 및 상기 화합물을 포함하는 조성물
|
CN101163489A
(zh)
*
|
2004-04-23 |
2008-04-16 |
细胞基因公司 |
用于治疗和控制肺高血压的包含免疫调节化合物的组合物及其使用方法
|
JP2005336157A
(ja)
*
|
2004-04-30 |
2005-12-08 |
Arigen Inc |
光学活性サリドマイドおよびその誘導体の製造法
|
CN1984657B
(zh)
*
|
2004-05-05 |
2010-12-15 |
细胞基因公司 |
用于治疗和控制骨髓增生性疾病的包含免疫调节化合物的组合物和使用方法
|
PL1765327T3
(pl)
*
|
2004-06-17 |
2015-01-30 |
Cytokinetics Inc |
Związki, kompozycje i sposoby
|
US7176222B2
(en)
|
2004-07-27 |
2007-02-13 |
Cytokinetics, Inc. |
Syntheses of ureas
|
NZ554068A
(en)
*
|
2004-09-03 |
2009-07-31 |
Celgene Corp |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
|
EP1811992A2
(en)
*
|
2004-10-28 |
2007-08-01 |
Celgene Corporation |
Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
|
KR20070086000A
(ko)
*
|
2004-11-12 |
2007-08-27 |
셀진 코포레이션 |
기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물
|
EP1827431A1
(en)
*
|
2004-11-23 |
2007-09-05 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
NZ565309A
(en)
*
|
2005-06-30 |
2011-03-31 |
Celgene Corp |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
KR20080026198A
(ko)
*
|
2005-06-30 |
2008-03-24 |
안트로제네시스 코포레이션 |
태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
|
EP1919365A2
(en)
*
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Ocular plug formed from placenta derived collagen biofabric
|
WO2007009062A2
(en)
*
|
2005-07-13 |
2007-01-18 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
MX2008002765A
(es)
*
|
2005-08-31 |
2008-04-07 |
Celgene Corp |
Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
|
EP2301535B1
(en)
|
2005-09-01 |
2014-05-28 |
Celgene Corporation |
Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
|
US20070066512A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
|
EP2530146A1
(en)
|
2005-10-13 |
2012-12-05 |
Anthrogenesis Corporation |
Immunomodulation using placental stem cells
|
AR058347A1
(es)
*
|
2005-12-15 |
2008-01-30 |
Cytokinetics Inc |
Entidades quimias composiciones y metodos
|
EP1959947A2
(en)
*
|
2005-12-15 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
US20070208000A1
(en)
*
|
2005-12-15 |
2007-09-06 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
US7825120B2
(en)
*
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
EP1959962A2
(en)
*
|
2005-12-16 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
WO2007078839A2
(en)
*
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
CN103060263B
(zh)
*
|
2005-12-29 |
2016-03-16 |
人类起源公司 |
胎盘干细胞群
|
US9598669B2
(en)
|
2005-12-29 |
2017-03-21 |
Anthrogenesis Corporation |
Composition for collecting placental stem cells and methods of using the composition
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
WO2007092569A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Battelle Memorial Institute |
Esters of 5 -hydroxymethylfurfural and methods for their preparation
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
TW200806625A
(en)
*
|
2006-05-26 |
2008-02-01 |
Astrazeneca Ab |
Therapeutic compounds
|
JP5523829B2
(ja)
*
|
2006-06-29 |
2014-06-18 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
US7993918B2
(en)
|
2006-08-04 |
2011-08-09 |
Anthrogenesis Corporation |
Tumor suppression using placental stem cells
|
US8105634B2
(en)
*
|
2006-08-15 |
2012-01-31 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
RU2448101C2
(ru)
*
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
EP2057143B1
(en)
*
|
2006-08-30 |
2013-07-24 |
Celgene Corporation |
5-substituted isoindoline compounds
|
ZA200901852B
(en)
*
|
2006-09-15 |
2010-06-30 |
Celgene Corp |
N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
|
WO2008042441A1
(en)
*
|
2006-10-03 |
2008-04-10 |
Anthrogenesis Corporation |
Use of umbilical cord biomaterial for ocular surgery
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
KR20190112868A
(ko)
|
2006-10-06 |
2019-10-07 |
안트로제네시스 코포레이션 |
천연(텔로펩티드) 태반 콜라겐 조성물
|
WO2008100497A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Anthrogenesis Corporation |
Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
|
KR101569168B1
(ko)
*
|
2007-02-12 |
2015-11-13 |
안트로제네시스 코포레이션 |
태반 줄기세포를 이용한 염증 질환의 치료
|
AU2008229383B2
(en)
*
|
2007-03-20 |
2013-09-05 |
Celgene Corporation |
4'-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
|
US20100172830A1
(en)
*
|
2007-03-29 |
2010-07-08 |
Cellx Inc. |
Extraembryonic Tissue cells and method of use thereof
|
US7893045B2
(en)
*
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
KR20190050867A
(ko)
*
|
2007-09-26 |
2019-05-13 |
안트로제네시스 코포레이션 |
인간 태반 관류액으로부터의 혈관형성 세포
|
NZ584425A
(en)
|
2007-09-26 |
2012-03-30 |
Celgene Corp |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
JP5795476B2
(ja)
*
|
2007-09-28 |
2015-10-14 |
アンスロジェネシス コーポレーション |
ヒト胎盤灌流液およびヒト胎盤由来中間ナチュラルキラー細胞を使用した腫瘍抑制
|
MX2010005018A
(es)
*
|
2007-11-07 |
2010-05-27 |
Anthrogenesis Corp |
Tratamiento de complicaciones de nacimiento prematuro.
|
CN101909609A
(zh)
*
|
2007-11-08 |
2010-12-08 |
细胞基因公司 |
免疫调节化合物在治疗与内皮功能障碍有关的紊乱中的用途
|
US20090155207A1
(en)
*
|
2007-11-29 |
2009-06-18 |
Hariri Robert J |
Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders
|
CA2710196A1
(en)
*
|
2007-12-20 |
2009-07-09 |
Celgene Corporation |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
MX2010008220A
(es)
*
|
2008-01-29 |
2010-08-23 |
Celgene Corp |
Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
DK2330889T3
(en)
*
|
2008-08-20 |
2017-01-30 |
Anthrogenesis Corp |
Improved cell composition and process for making the same
|
EP2329012B1
(en)
*
|
2008-08-20 |
2020-05-20 |
Celularity, Inc. |
Treatment of stroke using isolated placental cells
|
EP2331109B1
(en)
*
|
2008-08-22 |
2013-05-29 |
Anthrogenesis Corporation |
Methods and compositions for treatment of bone defects with placental cell populations
|
PT2358697E
(pt)
|
2008-10-29 |
2016-02-03 |
Celgene Corp |
Compostos de isoindolina para utilização no tratamento do cancro
|
WO2010059828A1
(en)
*
|
2008-11-19 |
2010-05-27 |
Anthrogenesis Corporation |
Amnion derived adherent cells
|
MX2011005230A
(es)
*
|
2008-11-21 |
2011-06-16 |
Anthrogenesis Corp |
Tratamiento de enfermedades, desordenes o condiciones del pulmon usando celulas de placenta.
|
WO2010077686A1
(en)
*
|
2008-12-08 |
2010-07-08 |
Sirtris Pharmaceuticals, Inc. |
Isoindolinone and related analogs as sirtuin modulators
|
WO2010111631A1
(en)
|
2009-03-25 |
2010-09-30 |
Anthrogenesis Corporation |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
WO2010137547A1
(ja)
|
2009-05-25 |
2010-12-02 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
CN101580501B
(zh)
*
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
US9226913B2
(en)
|
2010-01-05 |
2016-01-05 |
Celgene Corporation |
Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof
|
ES2646750T3
(es)
*
|
2010-01-26 |
2017-12-15 |
Anthrogenesis Corporation |
Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
|
NZ601289A
(en)
|
2010-02-11 |
2014-10-31 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
EP2555769B1
(en)
|
2010-04-07 |
2022-01-12 |
Amgen (Europe) GmbH |
Methods for treating respiratory viral infection
|
NZ630009A
(en)
|
2010-04-07 |
2016-05-27 |
Anthrogenesis Corp |
Angiogenesis using placental stem cells
|
KR20130092394A
(ko)
|
2010-04-08 |
2013-08-20 |
안트로제네시스 코포레이션 |
태반 줄기 세포를 사용한 사르코이드증의 치료
|
EP2593542B1
(en)
|
2010-07-13 |
2018-01-03 |
Anthrogenesis Corporation |
Methods of generating natural killer cells
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
EP2658557A1
(en)
|
2010-12-31 |
2013-11-06 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory rna molecules
|
WO2012125438A1
(en)
|
2011-03-11 |
2012-09-20 |
Celgene Corporation |
Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
EP2699091B1
(en)
|
2011-03-28 |
2017-06-21 |
DeuteRx, LLC |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
JP2014517915A
(ja)
|
2011-04-18 |
2014-07-24 |
セルジーン コーポレイション |
多発性骨髄腫治療のためのバイオマーカー
|
CA2834535A1
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
AU2012262273B2
(en)
|
2011-06-01 |
2017-09-14 |
Celularity Inc. |
Treatment of pain using placental stem cells
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
MX2014014668A
(es)
|
2012-06-06 |
2015-03-19 |
Bionor Immuno As |
Vacuna.
|
EP2867671B1
(en)
|
2012-06-29 |
2018-10-24 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
WO2014110558A1
(en)
|
2013-01-14 |
2014-07-17 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
CN115137753A
(zh)
|
2013-02-05 |
2022-10-04 |
细胞结构公司 |
来自胎盘的自然杀伤细胞
|
CA2941560A1
(en)
|
2013-03-14 |
2014-09-25 |
Deuterx, Llc |
3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
WO2014152177A1
(en)
|
2013-03-15 |
2014-09-25 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
CN103421061A
(zh)
*
|
2013-08-14 |
2013-12-04 |
中国药科大学 |
来那度胺衍生物、其制法及其医药用途
|
CN103396397A
(zh)
*
|
2013-08-14 |
2013-11-20 |
中国人民解放军军事医学科学院毒物药物研究所 |
来那度胺衍生物及其作为药物的用途
|
AU2014372638A1
(en)
*
|
2013-12-23 |
2016-06-16 |
Norgine B.V. |
Compounds useful as CCR9 modulators
|
MX2016013563A
(es)
*
|
2014-04-14 |
2017-05-09 |
Arvinas Inc |
Moduladores de la proteolisis basados en imida y metodos de uso asociados.
|
EP3827836A1
(en)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
CA2951616A1
(en)
|
2014-07-11 |
2016-01-14 |
Bionor Immuno As |
Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
|
FI3182996T3
(fi)
|
2014-08-22 |
2023-03-28 |
Celgene Corp |
Menetelmiä multippelin myelooman hoitamiseksi immuunivastetta muuntavilla yhdisteillä yhdistelmässä vasta-aineiden kanssa
|
US10017492B2
(en)
*
|
2014-10-30 |
2018-07-10 |
Kangpu Biopharmaceuticals, Ltd. |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
KR20220029783A
(ko)
|
2015-01-20 |
2022-03-08 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
WO2016177833A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
WO2016210262A1
(en)
|
2015-06-26 |
2016-12-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
US20180271849A1
(en)
*
|
2015-09-29 |
2018-09-27 |
Kangpu Biopharmaceuticals, Ltd. |
Pharmaceutical composition and application thereof
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
US11192898B2
(en)
*
|
2016-04-06 |
2021-12-07 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
JP7001614B2
(ja)
*
|
2016-04-06 |
2022-02-03 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
リガンド依存性の標的タンパク質分解のための単官能性中間体
|
EP3442976B1
(en)
*
|
2016-04-12 |
2022-07-20 |
The Regents of The University of Michigan |
Bet protein degraders
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
JP7009466B2
(ja)
|
2016-10-11 |
2022-02-10 |
アルビナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体の標的分解のための化合物および方法
|
AU2017367872B2
(en)
|
2016-11-01 |
2022-03-31 |
Arvinas, Inc. |
Tau-protein targeting protacs and associated methods of use
|
RU2750484C2
(ru)
|
2016-12-01 |
2021-06-28 |
Эрвинэс Оперейшнс, Инк. |
Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора
|
EP3548083A1
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
MA46963A
(fr)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics Inc |
Méthodes pour déterminer le dosage de céllules car-t
|
US10933059B2
(en)
*
|
2016-12-16 |
2021-03-02 |
Kangpu Biopharmaceuticals. Ltd. |
Combination, application thereof and treatment method
|
CA3047586A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas Operations, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
|
WO2018119448A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
KR20230140606A
(ko)
|
2017-01-26 |
2023-10-06 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
|
WO2017067530A2
(zh)
*
|
2017-02-13 |
2017-04-27 |
康朴生物医药技术(上海)有限公司 |
一种治疗前列腺癌的组合、药物组合物及治疗方法
|
IL270250B2
(en)
|
2017-05-01 |
2024-06-01 |
Juno Therapeutics Inc |
A combination of cellular therapy and an immune modulatory compound
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
CN118440096A
(zh)
|
2017-06-20 |
2024-08-06 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
US20220225597A1
(en)
|
2017-06-29 |
2022-07-21 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
CN109422751B
(zh)
*
|
2017-09-03 |
2022-04-22 |
上海美志医药科技有限公司 |
一类具有降解酪氨酸蛋白激酶jak3活性的化合物
|
CN111278815B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
戊二酰亚胺
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
EP3679027A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydrobenzimidazolones
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
WO2019067792A1
(en)
|
2017-09-28 |
2019-04-04 |
Celularity, Inc. |
TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
|
EP3703688A2
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
WO2019099868A2
(en)
|
2017-11-16 |
2019-05-23 |
C4 Therapeutics, Inc. |
Degraders and degrons for targeted protein degradation
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
JP7241036B2
(ja)
*
|
2018-01-25 |
2023-03-16 |
株式会社フジモト・コーポレーション |
チオフェン誘導体およびその用途
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
AU2019223076A1
(en)
|
2018-02-21 |
2020-10-08 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
CN111902141A
(zh)
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
KR20230130752A
(ko)
|
2018-04-04 |
2023-09-12 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
CN112312904A
(zh)
|
2018-04-16 |
2021-02-02 |
C4医药公司 |
螺环化合物
|
DK3784663T3
(da)
*
|
2018-04-23 |
2023-10-16 |
Celgene Corp |
Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
WO2020006264A1
(en)
*
|
2018-06-29 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Ligands to cereblon (crbn)
|
WO2020051235A1
(en)
*
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
BR112021008930A2
(pt)
|
2018-11-08 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos e combinações para o tratamento e modulação de célula t
|
EP3880669A1
(en)
*
|
2018-11-13 |
2021-09-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
WO2020102770A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
CN109293631B
(zh)
*
|
2018-11-30 |
2020-05-08 |
常州制药厂有限公司 |
3-氨基-n-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法
|
WO2020113194A2
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
AR119683A1
(es)
|
2019-01-29 |
2022-01-05 |
Juno Therapeutics Inc |
Anticuerpos y receptores de antígeno quimérico específicos para receptor huérfano 1 similar a receptor de tirosina quinasa (ror1)
|
US20230248696A1
(en)
*
|
2019-05-03 |
2023-08-10 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
JP2022533260A
(ja)
|
2019-05-24 |
2022-07-21 |
バイオセリックス, インコーポレイテッド |
タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用
|
AR119057A1
(es)
|
2019-05-31 |
2021-11-17 |
Celgene Corp |
Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
|
JP2022551185A
(ja)
*
|
2019-10-09 |
2022-12-07 |
モンテ ローザ セラピューティクス アーゲー |
イソインドリノン化合物
|
TWI836159B
(zh)
|
2019-11-19 |
2024-03-21 |
美商必治妥美雅史谷比公司 |
可作為helios蛋白質抑制劑之化合物
|
MX2022007678A
(es)
|
2019-12-19 |
2022-09-19 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
|
MX2022014071A
(es)
|
2020-05-09 |
2023-01-30 |
Arvinas Operations Inc |
Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo.
|
MX2023008296A
(es)
|
2021-01-13 |
2023-09-29 |
Monte Rosa Therapeutics Inc |
Compuestos de isoindolinona.
|
CN112876414B
(zh)
*
|
2021-01-29 |
2022-09-09 |
河南大学 |
一种基于多胺修饰的萘酰亚胺缀合物、其制备方法及应用
|
WO2022200857A1
(en)
*
|
2021-03-22 |
2022-09-29 |
Monte Rosa Therapeutics Ag |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
JP2024515243A
(ja)
|
2021-04-06 |
2024-04-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
ピリジニル置換されたオキソイソインドリン化合物
|
EP4333836A1
(en)
*
|
2021-05-07 |
2024-03-13 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
CN115504963A
(zh)
*
|
2021-06-22 |
2022-12-23 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白降解剂
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
CN114656374A
(zh)
*
|
2022-02-22 |
2022-06-24 |
营口兴福化工有限公司 |
2,4-二氯-3-氰基-5-氟苯甲酸合成方法
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
KR20240001072A
(ko)
*
|
2022-06-24 |
2024-01-03 |
주식회사 아이비스바이오 |
신규한 포말리도마이드 유도체 및 이의 제조방법
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
KR20240066904A
(ko)
*
|
2022-11-08 |
2024-05-16 |
주식회사 온코드바이오 |
아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
|